Although Pueraria lobata extract is generally considered to be a protective agent for cardiovascular and cerebrovascular diseases, the exact role of reducing reperfusion injury in myocardial infarction is unclear. This study aimed to integrate a randomized controlled trial based on a rat model to assess the effects of extracts on myocardial ischemia mechanisms. Related research was conducted in PubMed, Wanfang and China Knowledge Network. To assess the protective effect of Pueraria lobata extract on myocardial infarction reperfusion injury, at least 3 outcome indicators reported in the original study, including myocardial ischemia and myocardial infarction size, creatine kinase, methylene dioxygen, were extracted and aggregated.Methylamine (malondialdehyde) and superoxide dismutase. Pueraria lobata extract can effectively reduce the minimum myocardial infarct size after myocardial infarction (mean difference: 29.20, 95% CIs: 44.90-13.51, p=0.03). Pueraria extract directly caused a decrease in creatine kinase (mean difference: 6.89, 95% CIs: 9.40-4.38, p=0.01) and malondialdehyde (mean difference: 2.41, 95% CIs: 3.14-1.68, p=0.01). Serum superoxide dismutase (mean difference: 63.97, 95% CIs: 38.19-89.75, p < 0.01) was elevated. Pueraria lobata extract may protect myocardial tissue from myocardial ischemia by increasing superoxide dismutase and decreasing creatine kinase and malondialdehyde. However, more animal studies and randomized controlled clinical trials are needed to confirm these results.